Sugammadex is Cleared Rapidly and Primarily Unchanged via Renal Excretion

Pierre Peeters, Paul Passier, Jean Smeets, Alex Zwiers, Marcel de Zwart, Saskia van de Wetering-Krebbers, Marlou van Iersel, Sjoerd van Marle, Diels van den Dobbelsteen

To cite this version:
Pierre Peeters, Paul Passier, Jean Smeets, Alex Zwiers, Marcel de Zwart, et al.. Sugammadex is Cleared Rapidly and Primarily Unchanged via Renal Excretion. Biopharmaceutics & Drug Disposition, 2011, 32 (3), pp.159. 10.1002/bdd.747. hal-00618170

HAL Id: hal-00618170
https://hal.science/hal-00618170
Submitted on 1 Sep 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Abstract:
Sugammadex is a modified γ-cyclodextrin which rapidly reverses rocuronium- and vecuronium-induced neuromuscular blockade. Previous studies suggest that sugammadex is mostly excreted unchanged via the kidneys. This single-center, open-label, non-randomized study used 14C-labeled sugammadex to further investigate the excretion, metabolic and pharmacokinetic (PK) profiles of sugammadex in six healthy male volunteers. 14C-labeled sugammadex 4 mg/kg (0.025 MBq/kg of 14C-radioactivity) was administered as a single intravenous bolus. Blood, urine, feces, and exhaled air samples were collected at pre-defined intervals for assessment of sugammadex by liquid chromatography-mass spectrometry (LC-MS) and for radioactivity measurements. Adverse events were also assessed.

Excretion of sugammadex was rapid with ~70% of the dose excreted within 6 h and ~90% within 24 h. Less than 0.02% of radioactivity was excreted in feces or exhaled air. Ninety-five percent of the radioactivity detected in urine could be attributed to sugammadex, as determined by LC-MS, suggesting very limited metabolism of sugammadex. LC-MS analysis of plasma samples found that sugammadex accounted for 100% of total 14C-radioactivity in the plasma. In general, PK parameters determined from radioactivity and sugammadex plasma concentrations were very similar. Any adverse events were of mild-to-moderate intensity, and judged unrelated to sugammadex. These findings demonstrate that sugammadex is cleared rapidly, almost
Sugammadex is Cleared Rapidly and Primarily Unchanged via Renal Excretion

Pierre Peeters\textsuperscript{a,*}, Paul Passier\textsuperscript{a,†}, Jean Smeets\textsuperscript{a,‡}, Alex Zwiers\textsuperscript{a}, Marcel de Zwart\textsuperscript{a}, Saskia van de Wetering-Krebbers\textsuperscript{a}, Marlou van Iersel\textsuperscript{a}, Sjoerd van Marle\textsuperscript{b} and Diels van den Dobbelsteen\textsuperscript{a}

\textsuperscript{a}MSD, Oss, The Netherlands; \textsuperscript{b}PRA International, Zuidlaren, The Netherlands; \textsuperscript{†}Current address: Astellas, Leiderdorp, The Netherlands; \textsuperscript{‡}Current address: LAP&P consultants BV, Leiden, The Netherlands

Running title: RENAL CLEARANCE OF SUGAMMADEX

*Correspondence to: Pierre A.M. Peeters, PhD, Early Stage Development, MSD, Oss, The Netherlands.
Tel: +31 412 661377; Fax: +31 412 662506; Email: pierre.peeters2@merck.com

Sources of financial support: This study was supported by MSD, Oss, The Netherlands.

ABSTRACT

Sugammadex is a modified γ-cyclodextrin which rapidly reverses rocuronium- and vecuronium-induced neuromuscular blockade. Previous studies suggest that sugammadex is mostly excreted unchanged via the kidneys. This single-center, open-label, non-randomized study used \(^{14}\)C-labeled sugammadex to further investigate the excretion, metabolic and pharmacokinetic (PK) profiles of sugammadex in six healthy male volunteers. \(^{14}\)C-labeled sugammadex 4 mg/kg (0.025 MBq/kg of \(^{14}\)C-radioactivity) was administered as a single intravenous bolus. Blood, urine, feces, and exhaled air samples were collected at pre-defined intervals for assessment of sugammadex by liquid chromatography-mass spectrometry (LC-MS) and for radioactivity measurements. Adverse events were also assessed.

Excretion of sugammadex was rapid with ~70% of the dose excreted within 6 h and ~90% within 24 h. Less than 0.02% of radioactivity was excreted in feces or exhaled air. Ninety-five percent of the radioactivity detected in urine could be attributed to sugammadex, as determined by LC-MS, suggesting very limited metabolism of sugammadex. LC-MS analysis of plasma samples found that sugammadex accounted for 100% of total \(^{14}\)C-radioactivity in the plasma. In general, PK parameters determined from radioactivity and sugammadex plasma concentrations were very similar. Any adverse events were of mild-to-moderate intensity, and judged unrelated to sugammadex. These findings demonstrate that sugammadex is cleared rapidly, almost exclusively via the kidney, with minimal or no metabolism.

Key words: Sugammadex; Org 25969; pharmacokinetics; gamma-cyclodextrin
**Introduction**

The modified γ-cyclodextrin, sugammadex, was specifically designed to encapsulate the steroidal neuromuscular blocking agent rocuronium, with structural similarities meaning that it will also encapsulate vecuronium [1,2], and has the ability to rapidly reverse both moderate and deep rocuronium- or vecuronium-induced neuromuscular blockade [3–6]. Sugammadex is approved in various countries for the reversal of rocuronium- or vecuronium-induced neuromuscular blockade in adults at a recommended dose range of 2–16 mg/kg, depending on the level of blockade at the time of administration. It is also approved for the reversal of moderate rocuronium-induced blockade in pediatric patients at a dose of 2 mg/kg [7–9].

Previous studies evaluating the pharmacokinetic (PK) profile of sugammadex have suggested that the majority of an intravenously (i.v.) administered sugammadex dose is excreted unchanged by the kidneys [10–12]. At doses of 2, 4, and 8 mg/kg, the mean recovery of sugammadex in urine within 24 h of administration ranged from 58.8% to 80.4% of the administered dose [10]. Using higher than recommended doses of 32, 64, or 96 mg/kg, urinary recovery within 48 h of administration was ~90% of the administered dose [13]. Despite this relatively high urinary recovery of sugammadex, quantified by tandem liquid chromatography mass spectrometry (LC-MS), a minor role of metabolism in the clearance of sugammadex cannot be excluded. The use of 14C-labeled sugammadex enables determination of the extent of metabolism and the relative contribution of the various routes of excretion to elimination.

The aim of the current trial was to further elucidate the extent of sugammadex metabolism and the relative contribution of various routes of excretion at a therapeutic dose of 4 mg/kg in healthy volunteers. To achieve this, the pharmacokinetic parameters
derived from assessment of sample radioactivity were compared with those derived from a LC-MS assay.
Materials and Methods

Study design

This was a single-center, open-label, non-randomized study of six healthy adult male subjects, conducted at PRA International (Zuidlaren, The Netherlands). A total of six subjects were selected because this number is generally considered adequate for studies evaluating the disposition of $^{14}$C-labeled compounds. The study protocol was approved by an independent ethics committee (Stichting Beoordeling Ethiek Bio-Medisch Onderzoek, Assen, The Netherlands) and was conducted in compliance with the Declaration of Helsinki, the International Conference on Harmonization Guidelines, Good Clinical Practice, and current regulatory requirements.

Subjects

Subjects were eligible for inclusion in the study if they were aged between ≥18 years and ≤65 years, had normal 12-lead electrocardiogram (ECG) intervals (PR between ≥120 ms and ≤210 ms, QRS <120 ms and QTc ≤450 ms), no clinically relevant ECG abnormalities and a heart rate >50 beats per minute after 5 min rest, had a body mass index between ≥18 and ≤30 kg/m$^2$, and were in otherwise good health for their age. Major exclusion criteria were: evidence of renal or hepatic disease; a history of drug or alcohol abuse, or a positive drug or alcohol screen; smoking >5 cigarettes/day; hepatitis B, C or HIV infection; febrile illness within 3 days before administration of sugammadex, stool production less than once every 2 days; a history of sensitivity/idiosyncrasy to chemically-related compounds or excipients which may be used in the study or to any other unspecified drug in the past; and drug therapy (excluding paracetamol) within 2 weeks (or 1 month in the case of inducers or inhibitors of drug-metabolizing enzymes) of
administration of sugammadex. All subjects were required to give written informed consent before enrollment in the study.

**Study drug administration**

Each subject received a single i.v. bolus dose of $^{14}$C-labeled sugammadex at a therapeutic dose level of 4 mg/kg (with 0.025 MBq/kg bodyweight of $^{14}$C-radioactivity, about 1.85 MBq per subject); the radiolabel was located on each of the side chains (Figure 1). Study drug administration was performed on the morning of day 1, after an overnight fast of at least 10 h. The use of any concomitant prescription or non-prescription drug (with the exception of intermittent paracetamol) was prohibited during the entire treatment period (i.e. from sugammadex administration until follow-up).

Consumption of alcohol and strenuous physical exercise were prohibited from 24 and 48 h before sugammadex administration, respectively, until collection of the last PK blood sample. Subjects received a standardized meal on day 1 and were not allowed to smoke during the entire study period.

**Sample collection**

Blood samples for PK evaluation and measurement of radioactivity were collected pre-dose (not for radioactivity) and at regular pre-defined intervals at 2, 5, 10, 20, and 35 min and 1, 1.5, 2.5, 4, 6, 8, 12, 18, 24, and 48 h post-dose. Urine samples were collected for PK evaluation and quantification of radioactivity at pre-dose (−12 to 0 h) and at 0–6, 6–12, 12–24, and 24–48 h post-dose; sampling for quantification of radioactivity continued until at least 48–72 h post-dose. All urine samples were diluted 1:1 volume for volume with blank human plasma to stabilize drug-related material prior to storage. Feces samples were collected for measurement of radioactivity pre-dose (from 3 days before sugammadex administration) and at 0–12, 12–24, and 24–48 h
post-dose. Exhaled air samples were collected pre-dose and at pre-defined intervals post-dose (1, 2, 6 and 12 h) for radioactivity measurement after administration of $^{14}$C-labeled sugammadex.

All samples taken for PK evaluation and measurement of radioactivity were stored at –20°C.

**Sample analysis**

Sugammadex concentrations in plasma and urine were determined using a validated liquid chromatography-mass spectrometry (LC-MS) assay method after solid phase extraction (SPE). The sample volumes used for analysis were 250 µl and 100 µl for plasma and urine, respectively. Isolute® 96-well SPE plates with 25 mg Isolute® HAX sorbent material per well (Sopachem, Wageningen, The Netherlands) were used for SPE of plasma and urine samples.

Chromatographic separations were carried out using an HP1100 series Liquid Chromatograph (Agilent Technologies, Palo Alto, CA). Samples were injected by a HTS PAL autosampler (CTC Analytics, Switzerland) and pumped at a flow-rate of 1.0 ml/min through a Polaris C18-A PEEK (polyaryletheretherketone) high performance liquid chromatography analytical column (50 mm length x 4.6 mm internal diameter, 5 µm particle size; Varian, Inc., Palo Alto, CA) with a linear mobile phase gradient of 0.1% v/v formic acid in water and methanol at ratios of 70:30 to 20:80. The liquid chromatography eluate was split 1:10 before entering a Perkin-Elmer Sciex API 3000 triple-quadrupole mass spectrometer (Sciex Thornhill, ON, Canada) equipped with a turbo ion-spray interface (Applied Biosystems, Foster City, CA). The quadrupoles were operated with unit resolution in the negative ion mode. The resulting multiple reaction monitoring chromatograms were integrated using Analyst version 1.2 software (Sciex). The Watson
Drug Metabolism Laboratory Information Management System (version 6.3.0.03) software (Innaphase Corporation, Wayne, PA) was used for all calculations. Calibration curves for sugammadex in both human heparin plasma and human urine were constructed using linear weighted regression (weighting factor $1/Y^2$) and used to calculate sugammadex levels in the calibration, quality control and study samples.

For radioactivity analysis, reference standards of $^{14}$C-labeled sugammadex and [1-methyl-$^{14}$C]-caffeine were used to prepare quality control samples. Human plasma, urine, and feces matrices were used for the analysis of blank samples in analytical runs and to prepare quality control samples. All scintillation counting were performed using a Packard Tri-Carb™ 3100 liquid scintillation analyzer (Downers Grove, IL) equipped with low level counting mode (LLCM) and normal counting mode (NCM). All calculations were performed in Microsoft Excel (Redmond, WA). Results were recorded in ng sugammadex equivalents/ml for plasma, dpm/ml for urine, dpm/g for feces, and in dpm for exhaled air and medication (quality control) Samples were assayed as follows:

**Medication (quality control) samples**

Samples were assayed using an aliquot of the i.v. medication solution, transferred into a 20 ml counting vial and mixed with 10 ml of the scintillation cocktail (Ultima Gold). After 20 min, the sample was counted for 10 min on NCM of the scintillation counter. The administered radioactive dose was calculated by multiplying the mean ($n = 3$) measured radioactivity level per g by the exact administered weight of the i.v. solution.

**Plasma samples**

Samples were assayed using a 1000 µl aliquot of the plasma sample, transferred into a 20 ml counting vial and mixed with 10 ml of the scintillation cocktail (Ultima Gold). After
waiting at least 30 min, samples were counted on the LLCM of the scintillation counter until a statistical error (2 s) of 0.5% was obtained with a maximum counting time of 10 min.

**Urine samples**

Samples were assayed using a 1000 µl aliquot of the urine sample, transferred into a 7 ml counting vial and mixed with 5 ml of the scintillation cocktail (Ultima Gold). After waiting at least 30 min, samples were counted until a statistical error (2s) of 0.5% was obtained with a maximum counting time of 10 min. Samples with a $^{14}$C activity level of <$50000$ dpm/ml were counted on the LCCM; samples above $50000$ dpm/ml were counted on the NCM.

**Feces samples**

Samples were transferred into a fitting bucket per subject and per 24 h time period and homogenized with a minimum of water (1–2 weight equivalents). After homogenization, two 15 g aliquots were taken for determination of total $^{14}$C-radioactivity and two 50 g aliquots were taken for possible metabolite profiling. An aliquot of ~0.5 g of the feces homogenate to be analyzed was then dried at 50°C for at least 3 h and combusted for a max of 1 min using a Packard 307 Sample Oxidizer (Perkin Elmer Life Sciences, Groningen, The Netherlands). CarboSorb-E (7 ml) was used to absorb carbon dioxide. At the end of the combustion cycle, the absorber was mixed with 13 ml of the scintillant Perma Fluor E+, and samples were then placed in the liquid scintillation counter for at least 30 min before counting. Samples were counted until a statistical error (2 s) of 0.5% was obtained with a maximum counting time of 10 min. Samples with a $^{14}$C activity level
of <160000 dpm/ml were counted on the LCCM; samples >160000 dpm/ml were counted on the NCM.

**Exhaled air samples**

Ten ml of the scintillation cocktail (Emulsifier Safe) was mixed with the CO$_2$-trapped exhaled air sample to be analyzed. After at least 90 min, samples were counted on the LLCM until a statistical error (2 s) of 0.5% was obtained with a maximum counting time of 20 min.

On day 3, subjects were discharged from the study center if <1% of the radioactive dose (sum of the urine and feces) was measured in the days excreta and if the total cumulative excretion was >90% of the radioactive dose. Subjects remained in the study center if the above criteria were not met, for a maximum of 7 further days. A follow-up assessment was performed on day 10. Furthermore, if radioactivity exceeded 50 dpm/ml in the urine and/or 75 dpm per 100 mg feces at the time of discharge, subjects were requested to bring 24-h urine samples to the clinic every 2–3 days until the radioactivity decreased to below these limits.

PK analysis was performed by the Clinical Pharmacology and Kinetics Department of MSD (Oss, The Netherlands). Quantification of radioactivity in all matrices was performed by the Bioanalytical Laboratory of PRA International (Zuidlaren, The Netherlands).
**Pharmacokinetic analysis**

From the plasma concentration of sugammadex and radioactivity (expressed in mass equivalents of sugammadex) the following non-compartmental PK parameters were calculated: maximum plasma concentration, time to maximum plasma concentration, terminal elimination half life ($t_{1/2}$), effective $t_{1/2}$ ($t_{1/2\text{, effective}} = \log_2 e \cdot \text{MRT}[\text{mean residence time}]$), area under the concentration versus time curve from time zero to infinity (AUC$_{0-\infty}$), total plasma clearance, and volume of distribution at steady state.

Urine concentrations of sugammadex and radioactivity were used to calculate the cumulative amount excreted in the urine up to the end of the last collection interval ($A_{\text{cum,tlast}}$) as a percentage of the total dose administered. These parameters were then used to calculate renal clearance ($CL_R=A_{\text{cum,tlast}}/\text{AUC}_{0-\infty}$) and the fraction of the dose excreted unchanged in the urine ($fe=A_{\text{cum,tlast}}/\text{dose}$). Cumulative excretion was also calculated for the exhaled air and feces samples based on level of radioactivity.

**Statistical Analysis**

Descriptive statistics were calculated for the plasma concentrations of sugammadex and radioactivity by time point for the cumulative excretion of radioactivity and sugammadex, and for PK parameters.

The PK analyses were performed using SAS version 8.2 (SAS Institute Inc., Cary, NC).

**Safety**

The tolerability and safety of sugammadex were evaluated based on adverse event (AE) reporting, vital signs (including systolic and diastolic blood pressure and heart rate), ECG monitoring (12-lead ECG at screening, baseline, and 2, 35, and 60 min post dose,
and follow-up), physical examination, and clinical laboratory values (hematology, blood chemistry, and urinalysis). Information on AEs and serious AEs (SAEs) was obtained from regular questioning of the subjects or on clinical examination. AEs were categorized according to their severity and relation to the study drug and were coded using MedDRA (version 8.1; MedDRA Maintenance and Support Services Organization, Chantilly). Safety data were evaluated for the all-subjects-treated (AST) group.
Results

Enrollment and subject baseline characteristics

All six subjects who entered the study received the study medication and were evaluable for PK assessment. All six subjects were healthy Caucasian males with a mean (standard deviation [SD]) age of 52.8 (16.3) years, a mean (SD) weight of 75.8 (9.9) kg and a mean (SD) BMI of 23.8 (1.9) kg/m².

Safety and tolerability

Each of the subjects experienced one or more AEs, all of which were of mild or moderate intensity and resolved without sequelae. There were no SAEs or discontinuations because of AEs and none of the AEs were considered by the investigator to be related to sugammadex. The most frequent AEs were abnormally frequent urination (n = 3) and headache (n = 2). No clinically significant abnormalities in ECG findings, vital signs, or clinical laboratory results were reported.

Pharmacokinetic profile

Excretion of sugammadex was rapid, with ~70% (mean [range] of 73 [27–92]%) of the radioactive dose excreted within 6 h, 92 (81–102)% within 24 h, and 95 (83–105)% within 48 h. The mean total cumulative excretion of sugammadex, as analyzed both by total ¹⁴C-radioactivity and LC-MS, is presented in Figure 2. At 48 h the mean (range) total cumulative amount of sugammadex (quantified by LC-MS) recovered in the urine during 48 h was 91 (85–94)% of the dose (Table 1). So, on average, 95% of the radioactivity detected in the urine could be attributed to sugammadex, as analyzed by LC-MS, suggesting there was very limited, if any, metabolism of sugammadex.
Moreover, the cumulative amount of radioactivity excreted in either feces or exhaled air was <0.02% in all patients.

In plasma, sugammadex measured by LC-MS, accounted for 100% of the total $^{14}$C-radioactivity, illustrated by the overlapping concentration curves (Figure 3). This suggests that there were either no radiolabeled metabolites of sugammadex in the plasma or that they were present at extremely low concentrations. Generally, the PK parameters determined from radioactivity and sugammadex plasma concentrations were very similar (Table 1). The small difference in $t_{1/2}$ between these two methods of detection can be explained by the lower limit of quantification of the radioactivity measurements versus the LC-MS method of detection, resulting in a later time interval for determination of the $t_{1/2}$. In accordance with the similar plasma concentrations observed (Figure 3), comparison of the $\text{AUC}_{0-\infty}$ of $^{14}$C and sugammadex revealed that on average 100% of the radioactivity in the plasma could be attributed to sugammadex.
Discussion

This study aimed to determine the pharmacokinetics and excretion profile of $^{14}$C-sugammadex and compare them with sugammadex concentrations as determined by LC-MS analysis. Radiolabeled sugammadex was excreted rapidly and almost exclusively via the kidneys. Total $^{14}$C detection mirrored the concentrations determined by LC-MS both in the plasma and also in urine (Figures 2 and 3). Furthermore, in the urine collected over 48 h following dosing, the mean cumulative amount of sugammadex quantified by LC-MS in the urine was 91% of the dose. Moreover, 95% of the radioactivity detected in the urine was attributed to sugammadex. This suggests that there was minimal to no metabolism of sugammadex, which is consistent with the findings of previous studies evaluating sugammadex in surgical patients and healthy volunteers [10–13]. Less than 0.02% of the dose was excreted in exhaled air and feces, suggesting that in man these routes of excretion play no role in the clearance of sugammadex. Interestingly, in rat and dog, a minor role for excretion in feces is observed with 4.22–6.82% and 0.33–0.80%, respectively, of the dose collected in the feces. For $^{14}$C $\alpha$-cyclodextrin and $^{14}$C $\gamma$-cyclodextrin given i.v. to rat [14,15] excretion into the feces has also been demonstrated to be a minor route of excretion (3–8% of the dose); however, as shown in the current study, this route is not applicable for sugammadex in man.

In this trial, the mean total cumulative amount of radioactivity recovered in the urine during 48 h was 95 (range 83–105) %, suggesting that at the most only a small fraction of the radioactivity was unaccounted for. There may be many causes of incomplete recovery of the radiolabel in mass balance trials (such as technical limitations and tissue retention), and it is actually rare for the mass balance in radiolabeled excretion studies to truly achieve 100% recovery [16].
The minimal role of metabolism in the clearance of sugammadex is fully in line with the excretion profile of other cyclodextrins, which has been noted to be almost entirely renal [14,15,17,18], particularly in man. Subsequent profiling for metabolites in urine and plasma samples demonstrated that the major part of total radioactivity could be attributed to the parent compound, sugammadex (data on file).

Studies in volunteers and surgical patients receiving sugammadex to reverse rocuronium- or vecuronium-induced blockade have also demonstrated that the predominant route of elimination for the complex is via the renal route, and in the presence of sugammadex, the major route of elimination of rocuronium changes from the hepatic to the renal route [10–12]. Based on data from surgical patients and healthy volunteers, the cumulative excretion of rocuronium in the urine over 24 h is in the region of 12–26% and increases to up to 74% after administration of sugammadex 4–8 mg/kg [10–12,19–21]. Given the importance of renal elimination, the efficacy and safety of sugammadex has been assessed in patients with impaired renal clearance, most of whom were receiving dialysis. The available data suggest that sugammadex is well tolerated and effective in patients with severe renal impairment, albeit with reduced plasma clearance of sugammadex and a significantly prolonged terminal elimination half life and MRT [22,23]. However, despite longer retention of the sugammadex-rocuronium complex, no signs of recurarization were reported among renal patients in the 48 h after administration of rocuronium followed by sugammadex [22]. Currently, for patients with mild-to-moderate renal impairment (creatinine clearance ≥30 and <80 ml/min), the dose recommendations for sugammadex are the same as for other adult patients i.e. a single i.v. bolus dose of 2–16 mg/kg [8]. For patients with severe renal impairment (creatinine clearance <30 ml/min), including patients requiring dialysis, sugammadex is not
recommended at present. However, further safety and PK studies are ongoing in this patient population.

Sugammadex 4 mg/kg (containing 0.025 MBq/kg of $^{14}$C-radioactivity) was well tolerated in all six healthy male subjects in this study. There were no drug-related AEs and no clinically significant abnormalities, changes, or trends were found with respect to safety laboratory data, vital signs, or ECGs, further adding to the safety profile of sugammadex that has been generated to date.
Conclusion

In conclusion, this study in healthy volunteers shows an i.v. dose of sugammadex to be cleared rapidly and almost exclusively via the kidneys, with minimal fecal excretion and minimal to no metabolism, as determined by LC-MS analysis. The mean total recovery of radiolabel from all routes in 48 h at the dose of 4 mg/kg was 95%. Pharmacokinetic parameters were similar whether calculated from total $^{14}$C radioactivity assessments or by LC-MS estimation of sugammadex concentrations.
Acknowledgements

Dr Peter Wiegerinck and Eric Sperling (Radiolabel synthesis group, Dept. of Process Chemistry, MSD, Oss, The Netherlands) are acknowledged for the synthesis and analysis of the sugammadex radiolabel. Pharmacokinetic calculations for this manuscript were performed by Dennis Doorstam, BSc (MSD, Oss, The Netherlands).

Medical writing assistance was provided by Neil Venn, PhD (Prime Medica Ltd, Knutsford, UK) during the preparation of this manuscript. The design and conduct of the study, as well as analysis of the study data and opinions, conclusions, and interpretation of the data, were the responsibility of the authors.

Conflict of interest

Pierre Peeters, Alex Zwiers, Marcel de Zwart, Saskia van de Wetering-Krebbers, Marlou van Iersel, and Diels van den Dobbelsteen are employees of MSD (Oss, The Netherlands). Paul Passier and Jean Smeets were previously employees of MSD (Oss, The Netherlands).
References


6 Khuenl-Brady KS, Wattwil M, Vanacker BF, Lora-Tamayo JI, Rietbergen H, Alvarez-Gómez JA. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized,
controlled trial. *Anesth Analg* 2009; **110**: 64–73. DOI:
10.1213/ane.0b013e3181ac53c3


*Anesthesiology* 2005; **103**: 695–703.

*Anesthesiology* 2006; **104**: 631–633.

neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology 2007; 106: 935–943. DOI: 10.1097/01.anes.0000265152.78943.74


16 Roffey SJ, Obach RS, Gedge JI, Smith DA. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev 2007; 39: 17–43. DOI: 10.1080/03602530500952172


Table 1. Pharmacokinetic parameters based on $^{14}$C-radioactivity detection and sugammadex concentrations determined by LC-MS ($n =$ 6 subjects)

<table>
<thead>
<tr>
<th></th>
<th>$^{14}$C (expressed as sugammadex mass equivalents)</th>
<th>Sugammadex (LC-MS)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Geometric mean</td>
<td>Geometric CV (%)</td>
</tr>
<tr>
<td><strong>Urine</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$\text{CL}_R$ (ml/min)</td>
<td>92.7</td>
<td>29</td>
</tr>
<tr>
<td>Fraction excreted unchanged (% dose; last collection interval)$^a$</td>
<td>96.1</td>
<td>85–106</td>
</tr>
<tr>
<td><strong>Plasma</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$C_{\text{max}}$ (µg/ml)</td>
<td>33.0</td>
<td>22</td>
</tr>
<tr>
<td>$t_{\text{max}}$ (min)$^b$</td>
<td>4</td>
<td>2–5</td>
</tr>
<tr>
<td>$t_{1/2}$ (min)</td>
<td>190</td>
<td>20</td>
</tr>
<tr>
<td>$t_{1/2 \text{ effective}}$ (min)</td>
<td>110</td>
<td>16</td>
</tr>
<tr>
<td>$\text{AUC}_{0-\infty}$ (µg·min/ml)</td>
<td>2632</td>
<td>25</td>
</tr>
<tr>
<td>$\text{CL}$ (ml/min)</td>
<td>96.8</td>
<td>25</td>
</tr>
<tr>
<td>$V_{\text{ss}}$ (ml)</td>
<td>15360</td>
<td>19</td>
</tr>
</tbody>
</table>

$^a$Data presented as arithmetic mean and range; samples were taken until 48 h after dosing for measurement of sugammadex (LC-MS) in urine, and until 332 h after dosing for measurement of $^{14}$C in urine

$^b$Data presented as median and range

$\text{AUC}_{0-\infty}$, area-under-the-plasma concentration-time curve to time infinity; $C_{\text{max}}$, maximum plasma concentration; $\text{CL}$, plasma clearance; $\text{CL}_R$, renal clearance; CV, coefficient of variation; LC-MS, liquid chromatography-mass spectrometry; $t_{1/2}$, terminal half-life; $t_{1/2 \text{ effective}}$, effective half-life; $t_{\text{max}}$, time to $C_{\text{max}}$; $V_{\text{ss}}$, volume of distribution at steady state.
Figure 1. Structure of $^{14}$C-labeled sugammadex
*denotes position of radiolabel

71x70mm (300 x 300 DPI)
Figure 2. Mean (range) cumulative percentage of total $^{14}$C-radioactivity and sugammadex dose (determined by LC-MS) excreted in urine during 48 h (n = 6 subjects).

LC-MS, liquid chromatography with mass spectrometry detection.
Figure 3. Geometric mean (range) sugammadex plasma concentration on a logarithmic scale, determined by LC-MS and $^{14}$C-radioactivity (n = 6 subjects). LC-MS, liquid chromatography with mass spectrometry detection.
Sugammadex is Cleared Rapidly and Primarily Unchanged via Renal Excretion

Pierre Peeters*, Paul Passier†, Jean Smeets‡, Alex Zwiers, Marcel de Zwart,
Saskia van de Wetering-Krebbers, Marlou van Iersel, Sjoerd van Marle and Diels van den Dobbelsteen

*Correspondence to: Pierre A.M. Peeters, PhD, Early Stage Development, MSD, Oss, The Netherlands.
Tel: +31 412 661377; Fax: +31 412 662506; Email: pierre.peeters2@merck.com

Sources of financial support: This study was supported by MSD, Oss, The Netherlands.

Meetings at which the work has been presented: American Society for Clinical Pharmacology and Therapeutics (ASCPT) 110th Annual Meeting, March 18–21, 2009, Washington, DC. Peeters P, Passier P, Smeets J, Zwiers A, de Zwart M, van Marle, S.

Sugammadex is cleared rapidly and primarily in an unchanged form via renal excretion.

ABSTRACT

Sugammadex is a modified γ-cyclodextrin which rapidly reverses rocuronium- and vecuronium-induced neuromuscular blockade. Previous studies suggest that sugammadex is mostly excreted unchanged via the kidneys. This single-center, open-label, non-randomized study used \(^{14}\)C-labeled sugammadex to further investigate the excretion, metabolic and pharmacokinetic (PK) profiles of sugammadex in six healthy male volunteers. \(^{14}\)C-labeled sugammadex 4 mg/kg (0.025 MBq/kg of \(^{14}\)C-radioactivity) was administered as a single intravenous bolus. Blood, urine, feces, and exhaled air samples were collected at pre-defined intervals for assessment of sugammadex by liquid chromatography-mass spectrometry (LC-MS) PK, and for radioactivity measurements, and metabolite profiling. Adverse events were also assessed.

Excretion of sugammadex was rapid with ~70% of the dose excreted within 6 h and ~90% within 24 h. Less than 0.02% of radioactivity was excreted in feces or exhaled air. Ninety-five percent of the radioactivity detected in urine could be attributed to sugammadex, as determined by liquid chromatography-mass spectrometry (LC-MS), suggesting very limited metabolism of sugammadex. LC-MS analysis of plasma samples found that sugammadex accounted for 100% of total \(^{14}\)C-radioactivity in the plasma. However, as a result of post-sampling oxidation or a minor impurity in the dose formulation, high-performance liquid radiochromatography analysis of urine and plasma samples revealed up to nine radioactive peaks. In general, PK parameters determined from radioactivity and sugammadex plasma concentrations were very similar. Any adverse events were of mild-to-moderate intensity, and judged unrelated to sugammadex. These findings demonstrate that sugammadex is cleared rapidly, almost exclusively via the kidney, with minimal or no metabolism.
Key words: Sugammadex; Org 25969; pharmacokinetics; metabolism; gamma-cyclodextrin
Introduction

The modified \(\gamma\)-cyclodextrin, sugammadex, was specifically designed to encapsulate the steroidal neuromuscular blocking agent rocuronium, with structural similarities meaning that it will also encapsulate vecuronium [1,2], and has the ability to rapidly reverse both moderate and deep rocuronium- or vecuronium-induced neuromuscular blockade [3–6]. Sugammadex is approved in various countries for the reversal of rocuronium- or vecuronium-induced neuromuscular blockade in adults at a recommended dose range of 2–16 mg/kg, depending on the level of blockade at the time of administration. It is also approved for the reversal of moderate rocuronium-induced blockade in pediatric patients at a dose of 2 mg/kg [7–9].

Previous studies evaluating the pharmacokinetic (PK) profile of sugammadex have suggested that the majority of an intravenously (i.v.) administered sugammadex dose is excreted unchanged by the kidneys [10–12]. At doses of 2, 4, and 8 mg/kg, the mean recovery of sugammadex in urine within 24 h of administration ranged from 58.8% to 80.4% of the administered dose [10]. Using higher than recommended doses of 32, 64, or 96 mg/kg, urinary recovery within 48 h of administration was ~90% of the administered dose [13]. Despite this relatively high urinary recovery of sugammadex, quantified by tandem liquid chromatography mass spectrometry (LC-MS), a minor role of metabolism in the clearance of sugammadex cannot be excluded. The use of \(^{14}\)C-labeled sugammadex enables determination of the extent of metabolism and the relative contribution of the various routes of excretion to elimination.

The aim of the current trial was to further elucidate the extent of sugammadex metabolism and the relative contribution of various routes of excretion at a therapeutic dose of 4 mg/kg in healthy volunteers. To achieve this, the pharmacokinetic parameters
derived from assessment of sample radioactivity were compared with those derived from a LC-MS assay.
Materials and Methods

Study design

This was a single-center, open-label, non-randomized study of six healthy adult male subjects, conducted at PRA International (Zuidlaren, The Netherlands). A total of six subjects were selected because this number is generally considered adequate for studies evaluating the disposition of $^{14}$C-labeled compounds. The study protocol was approved by an independent ethics committee (Stichting Beoordeling Ethiek Bio-Medisch Onderzoek, Assen, The Netherlands) and was conducted in compliance with the Declaration of Helsinki, the International Conference on Harmonization Guidelines, Good Clinical Practice, and current regulatory requirements.

Subjects

Subjects were eligible for inclusion in the study if they were aged between $\geq 18$ years and $\leq 65$ years, had normal 12-lead electrocardiogram (ECG) intervals (PR between $\geq 120$ ms and $\leq 210$ ms, QRS $< 120$ ms and QTc $\leq 450$ ms), no clinically relevant ECG abnormalities and a heart rate $>50$ beats per minute after 5 min rest, had a body mass index between $\geq 18$ and $\leq 30$ kg/m$^2$, and were in otherwise good health for their age. Major exclusion criteria were: evidence of renal or hepatic disease; a history of drug or alcohol abuse, or a positive drug or alcohol screen; smoking $>5$ cigarettes/day; hepatitis B, C or HIV infection; febrile illness within 3 days before administration of sugammadex, stool production less than once every 2 days; a history of sensitivity/idiosyncrasy to chemically-related compounds or excipients which may be used in the study or to any other unspecified drug in the past; and drug therapy (excluding paracetamol) within 2 weeks (or 1 month in the case of inducers or inhibitors of drug-metabolizing enzymes) of
administration of sugammadex. All subjects were required to give written informed consent before enrollment in the study.

**Study drug administration**

Each subject received a single i.v. bolus dose of $^{14}$C-labeled sugammadex at a therapeutic dose level of 4 mg/kg (with 0.025 MBq/kg bodyweight of $^{14}$C-radioactivity, about 1.85 MBq per subject); the radiolabel was located on each of the side chains (Figure 1). Study drug administration was performed on the morning of day 1, after an overnight fast of at least 10 h. The use of any concomitant prescription or non-prescription drug (with the exception of intermittent paracetamol) was prohibited during the entire treatment period (i.e. from sugammadex administration until follow-up). Consumption of alcohol and strenuous physical exercise were prohibited from 24 and 48 h before sugammadex administration, respectively, until collection of the last PK blood sample. Subjects received a standardized meal on day 1 and were not allowed to smoke during the entire study period.

**Sample collection**

Blood samples for PK evaluation and measurement of radioactivity and metabolic profiling were collected pre-dose (not for radioactivity) and at regular pre-defined intervals at 2, 5, 10, 20, and 35 min and 1, 1.5, 2.5, 4, 6, 8, 12, 18, 24, and 48 h post-dose. The exceptions to this were that blood samples for radioactivity measurements were not collected pre-dose and samples for metabolite profiling were not collected at 2 and 5-min post-dose. Urine samples were collected for PK evaluation and quantification of radioactivity and metabolite profiling at pre-dose (−12 to 0 h) and at 0–6, 6–12, 12–24, and 24–48 h post-dose; sampling for quantification of radioactivity continued until at least 48–72 h post-dose. All urine samples were diluted 1:1 volume for volume with
blank human plasma to stabilize drug-related material prior to storage. Feces samples were collected for measurement of radioactivity and metabolite profiling pre-dose (from 3 days before sugammadex administration) and at 0–12, 12–24, and 24–48 h post-dose. Exhaled air samples were collected pre-dose and at pre-defined intervals post-dose (1, 2, 6 and 12 h) for radioactivity measurement after administration of $^{14}$C-labeled sugammadex.

All samples taken for PK evaluation and measurement of radioactivity and metabolite profiling were stored at $-20^\circ$C.

**Sample analysis**

Sugammadex concentrations in plasma and urine were determined using a validated liquid chromatography-mass spectrometry (LC-MS) assay method after solid phase extraction (SPE). The sample volumes used for analysis were 250 µl and 100 µl for plasma and urine, respectively. Isolute® 96-well SPE plates with 25 mg Isolute® HAX sorbent material per well (Sopachem, Wageningen, The Netherlands) were used for SPE of plasma and urine samples.

Chromatographic separations were carried out using an HP1100 series Liquid Chromatograph (Agilent Technologies, Palo Alto, CA). Samples were injected by a HTS PAL autosampler (CTC Analytics, Switzerland) and pumped at a flow-rate of 1.0 ml/min through a Polaris C18-A PEEK (polyaryletheretherketone) high performance liquid chromatography analytical column (50 mm length x 4.6 mm internal diameter, 5 µm particle size; Varian, Inc., Palo Alto, CA) with a linear mobile phase gradient of 0.1% v/v formic acid in water and methanol at ratios of 70:30 to 20:80. The liquid chromatography eluate was split 1:10 before entering a Perkin-Elmer Sciex API 3000 triple-quadrupole mass spectrometer (Sciex Thornhill, ON, Canada) equipped with a turbo ion-spray.
interface (Applied Biosystems, Foster City, CA). The quadrupoles were operated with unit resolution in the negative ion mode. The resulting multiple reaction monitoring chromatograms were integrated using Analyst version 1.2 software (Sciex). The Watson Drug Metabolism Laboratory Information Management System (version 6.3.0.03) software (Innaphase Corporation, Wayne, PA) was used for all calculations. Calibration curves for sugammadex in both human heparin plasma and human urine were constructed using linear weighted regression (weighting factor $1/Y^2$) and used to calculate sugammadex levels in the calibration, quality control and study samples.

For radioactivity analysis, reference standards of $^{14}$C-labeled sugammadex and [1-methyl-$^{14}$C]-caffeine were used to prepare quality control samples. Human plasma, urine, and feces matrices were used for the analysis of blank samples in analytical runs and to prepare quality control samples. All scintillation counting were performed using a Packard Tri-Carb™ 3100 liquid scintillation analyzer (Downers Grove, IL) equipped with low level counting mode (LLCM) and normal counting mode (NCM). All calculations were performed in Microsoft Excel (Redmond, WA). Results were recorded in ng sugammadex equivalents/ml for plasma, dpm/ml for urine, dpm/g for feces, and in dpm for exhaled air and medication (quality control) Samples were assayed as follows:

**Medication (quality control) samples**

Samples were assayed using an aliquot of the i.v. medication solution, transferred into a 20 ml counting vial and mixed with 10 ml of the scintillation cocktail (Ultima Gold). After 20 min, the sample was counted for 10 min on NCM of the scintillation counter. The administered radioactive dose was calculated by multiplying the mean ($n = 3$) measured radioactivity level per g by the exact administered weight of the i.v. solution.

http://mc.manuscriptcentral.com/bdd
**Plasma samples**

Samples were assayed using a 1000 µl aliquot of the plasma sample, transferred into a 20 ml counting vial and mixed with 10 ml of the scintillation cocktail (Ultima Gold). After waiting at least 30 min, samples were counted on the LLCM of the scintillation counter until a statistical error (2 s) of 0.5% was obtained with a maximum counting time of 10 min.

**Urine samples**

Samples were assayed using a 1000 µl aliquot of the urine sample, transferred into a 7 ml counting vial and mixed with 5 ml of the scintillation cocktail (Ultima Gold). After waiting at least 30 min, samples were counted until a statistical error (2s) of 0.5% was obtained with a maximum counting time of 10 min. Samples with a $^{14}$C activity level of < 50000 dpm/ml were counted on the LCCM; samples above 50000 dpm/ml were counted on the NCM.

**Feces samples**

Samples were transferred into a fitting bucket per subject and per 24 h time period and homogenized with a minimum of water (1–2 weight equivalents). After homogenization, two 15 g aliquots were taken for determination of total $^{14}$C-radioactivity and two 50 g aliquots were taken for possible metabolite profiling. An aliquot of ~0.5 g of the feces homogenate to be analyzed was then dried at 50°C for at least 3 h and combusted for a max of 1 min using a Packard 307 Sample Oxidizer (Perkin Elmer Life Sciences, Groningen, The Netherlands). CarboSorb-E (7 ml) was used to absorb carbon dioxide. At the end of the combustion cycle, the absorber was mixed with 13 ml of the scintillant Perma Fluor E+, and samples were then placed in the liquid scintillation counter for at
least 30 min before counting. Samples were counted until a statistical error (2 s) of 0.5% was obtained with a maximum counting time of 10 min. Samples with a $^{14}$C activity level of $<160000$ dpm/ml were counted on the LCCM; samples $>160000$ dpm/ml were counted on the NCM.

**Exhaled air samples**

Ten ml of the scintillation cocktail (Emulsifier Safe) was mixed with the CO$_2$-trapped exhaled air sample to be analyzed. After at least 90 min, samples were counted on the LLCM until a statistical error (2 s) of 0.5% was obtained with a maximum counting time of 20 min.

On day 3, subjects were discharged from the study center if $<1\%$ of the radioactive dose (sum of the urine and feces) was measured in the days excreta and if the total cumulative excretion was $>90\%$ of the radioactive dose. Subjects remained in the study center if the above criteria were not met, for a maximum of 7 further days. A follow-up assessment was performed on day 10. Furthermore, if radioactivity exceeded 50 dpm/ml in the urine and/or 75 dpm per 100 mg feces at the time of discharge, subjects were requested to bring 24-h urine samples to the clinic every 2–3 days until the radioactivity decreased to below these limits.

PK analysis was performed by the Clinical Pharmacology and Kinetics Department of MSD (Oss, The Netherlands). Quantification of radioactivity in all matrices was performed by the Bioanalytical Laboratory of PRA International (Zuidlaren, The Netherlands). Radioactive high performance liquid chromatography (HPLC) for metabolite profiling and identification by mass spectrometry was performed by Huntingdon Life Sciences Ltd (Huntingdon, UK).
**Metabolite profiling**

A total of 36 plasma samples (consisting of the samples taken 20 min, 1, 1.5, 2.5, 4, and 6 h after sugammadex administration from each subject), 14 urine samples (consisting of the 0–6 and 6–12 h post-sugammadex samples from all subjects, and the 12–24 and 24–48 h post-sugammadex samples from one subject with protracted urinary excretion of sugammadex) and one sample of the original dose formulation were used for metabolite profiling.

The plasma samples taken 20 min after sugammadex administration and urine samples collected at 0–6 and 6–12 h after sugammadex administration were analyzed as individual samples. A representative plasma sample of 1–6 h post-sugammadex administration was prepared for each subject by pooling equal volume aliquots from each of the 1, 1.5, 2.5, 4, and 6 h samples. Furthermore, a representative urine sample of 6–48 h after sugammadex administration was prepared for one subject with protracted renal excretion by pooling equal percentages by volume of the 6–12, 12–24, and 24–48 h samples.

Samples were then used for metabolite profiling after partial purification by solid phase extraction by a validated HPLC method. In samples in which radioactivity was sufficiently high, radioactive components were quantified using the on-line radioactivity detector software (Laura V1.4a, Lablogic, Bioscan, Washington, DC). Where sample radioactivity levels were too low for quantification by this method, fractions of HPLC eluate/scintillator were collected at 0.5 min intervals for the full duration of the analysis using an automatic fraction collector and the radioactive concentration determined. The total radioactivity associated with each radioactive component detected was expressed as a proportion of the total radioactivity eluted. Qualitative LC-MS analysis of a 0–6 h urine sample, as well as reference standards of $^{14}$C-labeled sugammadex, unlabeled...
sugammadex, a related cyclodextrin, and two monosulphoxides of sugammadex, was performed to aid metabolite identification.

Pharmacokinetic analysis

From the plasma concentration of sugammadex and radioactivity (expressed in mass equivalents of sugammadex) the following non-compartmental PK parameters were calculated: maximum plasma concentration, time to maximum plasma concentration, terminal elimination half life \((t_{1/2})\), effective \(t_{1/2}\) \(t_{1/2, \text{effective}}=\log_2 2 \cdot \text{MRT[mean residence time]}\), area under the concentration versus time curve from time zero to infinity \((\text{AUC}_{0-\infty})\), total plasma clearance, and volume of distribution at steady state.

Urine concentrations of sugammadex and radioactivity were used to calculate the cumulative amount excreted in the urine up to the end of the last collection interval \((\text{Ae}_{\text{cum,tlast}})\) as a percentage of the total dose administered. These parameters were then used to calculate renal clearance \((\text{CL}_R=\frac{\text{Ae}_{\text{cum,tlast}}}{\text{AUC}_{0-\infty}})\) and the fraction of the dose excreted unchanged in the urine \((\text{fe}=\frac{\text{Ae}_{\text{cum,tlast}}}{\text{dose}})\). Cumulative excretion was also calculated for the exhaled air and feces samples based on level of radioactivity.

Statistical Analysis

Descriptive statistics were calculated for the plasma concentrations of sugammadex and radioactivity by time point for the cumulative excretion of radioactivity and sugammadex, and for PK parameters.

The PK analyses were performed using SAS version 8.2 (SAS Institute Inc., Cary, NC).
**Safety**

The tolerability and safety of sugammadex were evaluated based on adverse event (AE) reporting, vital signs (including systolic and diastolic blood pressure and heart rate), ECG monitoring (12-lead ECG at screening, baseline, and 2, 35, and 60 min post dose, and follow-up), physical examination, and clinical laboratory values (hematology, blood chemistry, and urinalysis). Information on AEs and serious AEs (SAEs) was obtained from regular questioning of the subjects or on clinical examination. AEs were categorized according to their severity and relation to the study drug and were coded using MedDRA (version 8.1; MedDRA Maintenance and Support Services Organization, Chantilly). Safety data were evaluated for the all-subjects-treated (AST) group.
Results

Enrollment and subject baseline characteristics

All six subjects who entered the study received the study medication and were evaluable for PK assessment. All six subjects were healthy Caucasian males with a mean (standard deviation [SD]) age of 52.8 (16.3) years, a mean (SD) weight of 75.8 (9.9) kg and a mean (SD) BMI of 23.8 (1.9) kg/m².

Safety and tolerability

Each of the subjects experienced one or more AEs, all of which were of mild or moderate intensity and resolved without sequelae. There were no SAEs or discontinuations because of AEs and none of the AEs were considered by the investigator to be related to sugammadex. The most frequent AEs were abnormally frequent urination (n = 3) and headache (n = 2). No clinically significant abnormalities in ECG findings, vital signs, or clinical laboratory results were reported.

Pharmacokinetic profile

Excretion of sugammadex was rapid, with ~70% (mean [range] of 73 [27–92]%) of the radioactive dose excreted within 6 h, 92 (81–102)% within 24 h, and 95 (83–105)% within 48 h. The median mean total cumulative excretion of sugammadex, as analyzed both by total ¹⁴C-radioactivity and LC-MS, is presented in Figure 2. At 48 h the mean (range) total cumulative amount of sugammadex (quantified by LC-MS) recovered in the urine during 48 h was 91 (85–94)% of the dose (Table 1). So, on average, 95% of the radioactivity detected in the urine could be attributed to sugammadex, as analyzed by LC-MS, suggesting there was very limited, if any, metabolism of sugammadex.
Moreover, the cumulative amount of radioactivity excreted in either feces or exhaled air was <0.02% in all patients.

In plasma, sugammadex measured by LC-MS, accounted for 100% of the total \(^{14}\)C-radioactivity, illustrated by the overlapping concentration curves (Figure 3). This suggests that there were either no radiolabeled metabolites of sugammadex in the plasma or that they were present at extremely low concentrations. Generally, the PK parameters determined from radioactivity and sugammadex plasma concentrations were very similar (Table 1). The small difference in \(t_{1/2}\) between these two methods of detection can be explained by the lower limit of quantification of the radioactivity measurements versus the LC-MS method of detection, resulting in a later time interval for determination of the \(t_{1/2}\). In accordance with the similar plasma concentrations observed (Figure 3), comparison of the AUC\(_{0-\infty}\) of \(^{14}\)C and sugammadex revealed that on average 100% of the radioactivity in the plasma could be attributed to sugammadex.

**Metabolite profiling**

Metabolite profiling of plasma and urine samples revealed the presence of up to nine radioactive peaks (designated M1–M9) (Figure 4A–D). The amount of radioactivity in the feces samples was too low (<0.02% cumulative radioactivity) to allow metabolite profiling. Most radioactivity in all plasma and urine samples was associated with M8 (co-eluting with sugammadex and identified by mass spectrometry) and most of the remaining radioactivity was associated with M6 and M7 (collectively associated with 14 to 28% of radioactivity in plasma samples, 8 to 12% of radioactivity in 0–6 h urine samples and 23 to 30% in ≥6 h urine samples [Tables 2A and B]). Peaks M6 and M7 were consistent with two of the reference standards, both monosulphoxides of sugammadex, as determined by LC-MS. Peaks M3, M4, and M5 each accounted for
<4% of radioactivity and M9 accounted for <3% of radioactivity. M1 and M2 were mostly associated with <1% and occasionally 4% of radioactivity, and were present in only some of the samples. In the sugammadex dose formulation, four peaks were observed (Figure 4E): a major peak representing 94% of the radioactivity and consistent with 14C-sugammadex, and three minor peaks, two of which were consistent with reference standards (and peaks M6 and M7 in the plasma and urine samples), and accounting for 1.1 and 1.6% of total radioactivity, respectively. The fourth peak accounted for 2% of radioactivity, did not co-elute with any reference standards, but was consistent with peak M9 observed in the patient samples and was also present in a similar proportion to that observed in patient samples. Therefore M9 can be excluded as a metabolite, and most likely this peak relates to a minor impurity in the 14C-sugammadex dose formulation. Org 48302 (substituted with one hydroxyl group on one of the eight glucosyl units instead of the thiopropionate group) did not co-elute with any of the radioactive peaks (data not shown), indicating that this related γ-cyclodextrin is not a metabolite of sugammadex.
Discussion

This study aimed to determine the pharmacokinetics and excretion profile of $^{14}$C-sugammadex and compare them with sugammadex concentrations as determined by LC-MS analysis. Radiolabeled sugammadex was excreted rapidly and almost exclusively via the kidneys. Total $^{14}$C detection mirrored the concentrations determined by LC-MS both in the plasma and also in urine (Figures 2 and 3). Furthermore, in the urine collected over 48 h following dosing, the mean cumulative amount of sugammadex quantified by LC-MS in the urine was 91% of the dose. Moreover, 95% of the radioactivity detected in the urine was attributed to sugammadex. This suggests that there was minimal to no metabolism of sugammadex, which is consistent with the findings of previous studies evaluating sugammadex in surgical patients and healthy volunteers [10–13]. Less than 0.02% of the dose was excreted by in exhaled air and feces, suggesting that in man these routes of excretion play no role in the clearance of sugammadex. Interestingly, in rat and dog, a minor role for excretion in feces is observed with 4.22–6.82% and 0.33–0.80%, respectively, of the dose collected in the feces. For $^{14}$C $\alpha$-cyclodextrin and $^{14}$C $\gamma$-cyclodextrin given i.v. to rat [14,15] excretion into the feces has also been demonstrated to be a minor route of excretion (3–8% of the dose); however, as shown in the current study, this route is not applicable for sugammadex in man.

In this trial, the mean total cumulative amount of radioactivity recovered in the urine during 48 h was 95 (range 83–105) %, suggesting that at the most only a small fraction of the radioactivity was unaccounted for. There may be many causes of incomplete recovery of the radiolabel in mass balance trials (such as technical limitations and tissue retention), and it is actually rare for the mass balance in radiolabeled excretion studies to truly achieve 100% recovery [16].
Subsequent metabolite profiling, performed on plasma and urine samples (stored at –20°C) approximately 8 months after the LC-MS analysis, visualized up to nine radioactive peaks in high performance liquid radiochromatograms of urine and plasma samples from the subjects involved in this trial. Three of these peaks also eluted when a sample of dose formulation underwent high performance liquid radiochromatography, but the radioactivity associated with two of these peaks, consistent with monosulphoxides of sugammadex, was found at considerably lower concentrations than in the patient samples. Although formation of these monosulphoxides by metabolism in vivo up to a few percent cannot be formally excluded, the presence of additional peaks in these samples is most likely the result of selective oxidation of the radiolabeled sugammadex in the plasma and urine samples during storage or sample work-up. Further evidence for this comes from the lower amount of 14C-radioactivity eluted in the M8 sugammadex peak corresponding with unchanged sugammadex during the high performance liquid radiochromatography compared with LC-MS analysis. The selective oxidation of 14C-sugammadex has also been noted when rat plasma was spiked with the radiolabel; the radiochemical purity of [14C]-sugammadex appeared to decrease from ≥99% to ≥84% during a 3 h incubation at 37°C, although unlabeled sugammadex is fully stable under these conditions. It is well known that in particular sulphur in 14C-labeled compounds is very sensitive to radio oxidation. The minimal role of metabolism in the clearance of sugammadex is fully in line with the excretion profile of other cyclodextrins, which has been noted to be almost entirely renal [14, 15, 17, 18], particularly in man. Subsequent profiling for metabolites in urine and plasma samples demonstrated that the major part of total radioactivity could be attributed to the parent compound, sugammadex (data on file).
Studies in volunteers and surgical patients receiving sugammadex to reverse rocuronium- or vecuronium-induced blockade have also demonstrated that the predominant route of elimination for the complex is via the renal route, and in the presence of sugammadex, the major route of elimination of rocuronium changes from the hepatic to the renal route [10–12]. Based on data from surgical patients and healthy volunteers, the cumulative excretion of rocuronium in the urine over 24 h is in the region of 12–26% and increases to up to 74% after administration of sugammadex 4–8 mg/kg [10–12,19–21]. Given the importance of renal elimination, the efficacy and safety of sugammadex has been assessed in patients with impaired renal clearance, most of whom were receiving dialysis. The available data suggest that sugammadex is well tolerated and effective in patients with severe renal impairment, albeit with reduced plasma clearance of sugammadex and a significantly prolonged terminal elimination half life and MRT [22,23]. However, despite longer retention of the sugammadex-rocuronium complex, no signs of recurarization were reported among renal patients in the 48 h after administration of rocuronium followed by sugammadex [22]. Currently, for patients with mild-to-moderate renal impairment (creatinine clearance ≥30 and <80 ml/min), the dose recommendations for sugammadex are the same as for other adult patients i.e. a single i.v. bolus dose of 2–16 mg/kg [8]. For patients with severe renal impairment (creatinine clearance <30 ml/min), including patients requiring dialysis, sugammadex is not recommended at present. However, further safety and PK studies are ongoing in this patient population.

Sugammadex 4 mg/kg (containing 0.025 MBq/kg of $^{14}$C-radioactivity) was well tolerated in all six healthy male subjects in this study. There were no drug-related AEs and no clinically significant abnormalities, changes, or trends were found with respect to
safety laboratory data, vital signs, or ECGs, further adding to the safety profile of sugammadex that has been generated to date.
Conclusion

In conclusion, this study in healthy volunteers shows an i.v. dose of sugammadex to be cleared rapidly and almost exclusively via the kidneys, with minimal fecal excretion and minimal to no metabolism, as determined by LC-MS analysis. The mean total recovery of radiolabel from all routes in 48 h at the dose of 4 mg/kg was 95%. Pharmacokinetic parameters were similar whether calculated from total $^{14}$C radioactivity assessments or by LC-MS estimation of sugammadex concentrations. The formation of the monosulphoxide-related $\gamma$-cyclodextrins is due to selective post-sampling oxidation of the $^{14}$C-sugammadex radiolabel and metabolism plays no significant role in the clearance of sugammadex.
Acknowledgements

Dr Peter Wiegerinck and Eric Sperling (Radiolabel synthesis group, Dept. of Process Chemistry, MSD, Oss, The Netherlands) are acknowledged for the synthesis and analysis of the sugammadex radiolabel. Brian John, PhD, Karen Fitzpatrick, MSc, and Andrew Hackett, PhD (Huntingdon Life Sciences, Huntingdon, UK) are acknowledged for the metabolite profiling. Pharmacokinetic calculations for this manuscript were performed by Dennis Doorstam, BSc (MSD, Oss, The Netherlands).

Medical writing assistance was provided by Neil Venn, PhD (Prime Medica Ltd, Knutsford, UK) during the preparation of this manuscript. The design and conduct of the study, as well as analysis of the study data and opinions, conclusions, and interpretation of the data, were the responsibility of the authors.

Conflict of interest

Pierre Peeters, Alex Zwiers, Marcel de Zwart, Saskia van de Wetering-Krebbers, Marlou van Iersel, and Diels van den Dobbelsteen are employees of MSD (Oss, The Netherlands). Paul Passier and Jean Smeets were previously employees of MSD (Oss, The Netherlands).
References


5 Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. *Anesthesiology* 2008; **109**: 816–824. DOI: 10.1097/ALN.0b013e31818a3fee

6 Khuenl-Brady KS, Wattwil M, Vanacker BF, Lora-Tamayo JI, Rietbergen H, Alvarez-Gómez JA. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized,
controlled trial. *Anesth Analg* 2009; **110**: 64–73. DOI:
10.1213/ane.0b013e3181ac53c3


neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. *Anesthesiology* 2007; **106**: 935–943. DOI: 10.1097/01.anes.0000265152.78943.74


16 Roffey SJ, Obach RS, Gedge JI, Smith DA. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev 2007; **39**: 17–43. DOI: 10.1080/03602530600952172


Table 1. Pharmacokinetic parameters based on $^{14}$C-radioactivity detection and sugammadex concentrations determined by LC-MS ($n = 6$ subjects)

<table>
<thead>
<tr>
<th></th>
<th>$^{14}$C</th>
<th>Sugammadex (LC-MS)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(expressed as sugammadex mass equivalents)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Geometric mean</td>
<td>Geometric CV (%)</td>
</tr>
<tr>
<td><strong>Urine</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CL$_R$ (ml/min)</td>
<td>92.7</td>
<td>29</td>
</tr>
<tr>
<td>fraction excreted</td>
<td>96.1</td>
<td>85–106</td>
</tr>
<tr>
<td>unchanged (% dose; last collection interval)$^a$</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Plasma</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$C_{max}$ (µg/ml)</td>
<td>33.0</td>
<td>22</td>
</tr>
<tr>
<td>$t_{max}$ (min)$^b$</td>
<td>4</td>
<td>2–5</td>
</tr>
<tr>
<td>$t_{1/2}$ (min)</td>
<td>190</td>
<td>20</td>
</tr>
<tr>
<td>$t_{1/2}$ effective (min)</td>
<td>110</td>
<td>16</td>
</tr>
<tr>
<td>AUC$_{0-\infty}$ (µg·min/ml)</td>
<td>2632</td>
<td>25</td>
</tr>
<tr>
<td>CL (ml/min)</td>
<td>96.8</td>
<td>25</td>
</tr>
<tr>
<td>$V_{ss}$ (ml)</td>
<td>15360</td>
<td>19</td>
</tr>
</tbody>
</table>

$^a$Data presented as arithmetic mean and range; samples were taken until 48 h after dosing for measurement of sugammadex (LC-MS) in urine, and until 332 h after dosing for measurement of $^{14}$C in urine

$^b$Data presented as median and range

AUC$_{0-\infty}$, area-under-the-plasma concentration-time curve to time infinity; $C_{max}$, maximum plasma concentration; CL, plasma clearance; CL$_R$, renal clearance; CV, coefficient of variation; LC-MS, liquid chromatography-mass spectrometry; $t_{1/2}$, terminal half-life; $t_{1/2}$ effective, effective half-life; $t_{max}$, time to $C_{max}$; $V_{ss}$, volume of distribution at steady state.